Lung Cancer News and Research

Latest Lung Cancer News and Research

Pinpoint Genomics makes Pinpoint Dx Lung Assay available to clinicians, patients

Pinpoint Genomics, Inc. announced the publication of key data relating to its Pinpoint Dx Lung Assay in the journal The Lancet, and the availability of its Pinpoint Dx Lung Assay to clinicians and patients exclusively through the company's laboratory in Mountain View, CA.

30 Jan 2012

HHMI honors EMBL Monterotondo researcher with International Early Career Scientist award

Rocio Sotillo, a staff scientist at the European Molecular Biology Laboratory (EMBL) in Monterotondo, is one of 28 outstanding young biomedical scientists who have been honoured with a Howard Hughes Medical Institute (HHMI) International Early Career Scientist award this year.

25 Jan 2012

Elevated blood lead levels put smokers at higher risk for renal cell carcinoma

Higher than normal levels of lead in the blood may signal a risk two times higher than average of developing renal cell carcinoma in smokers, according to medical researchers.

24 Jan 2012

Study provides valuable information on which cancer patients might need help to quit smoking

A new analysis has found that a substantial number of lung and colorectal cancer patients continue to smoke after being diagnosed. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study provides valuable information on which cancer patients might need help to quit smoking.

23 Jan 2012

Combination of gefitinib and miRNA-inhibitor might effectively treat NSCLC

New research published in Nature Medicine indicates that targeted drugs such as gefitinib might more effectively treat non-small cell lung cancer if they could be combined with agents that block certain microRNAs.

20 Jan 2012

Study examines drug resistance in ALK positive lung cancer

Scientists from the University of Colorado Cancer Center have once again advanced the treatment of a specific kind of lung cancer. The team has documented how anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) becomes resistant to a drug targeting the abnormal protein in the cancer. It's the first time scientists have analyzed the frequency and type of drug resistance in ALK positive patients taking crizotinib.

19 Jan 2012

Rexahn receives approval to initiate RX-3117 Phase I trial in solid tumors

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing oncology and CNS therapeutics, today announced that it has secured Hungarian Regulatory Authority and Ethics Committee approval for Rexahn's initial Clinical Trial Application.

19 Jan 2012

Book outlines digital future of medicine

The inventions of cell phones, personal computers, and the Internet ushered in the digital revolution and altered our existence in ways that were unimaginable just a few decades ago. But the most precious part of our existence-our health-has so far been largely unaffected and insulated from these innovations.

19 Jan 2012

TB associated with EGFR mutations in patients with lung adenocarcinoma

Tuberculosis (TB) has been suspected to increase a person's risk of lung cancer because the pulmonary inflammation and fibrosis can induce genetic damage. However, direct evidence of specific genetic changes and the disease have not been extensively reported.

19 Jan 2012

BJALCF receives $1 million in grants for 2012 Lung Cancer Research

Just two months shy of marking its 7-year anniversary, BJALCF announced today that it has awarded over $1 million in grants for 2012 Lung Cancer Research. BJALCF has made a promise to the Lung Cancer Community to fund only immediate results-oriented projects or programs promising to catalyze progress through early detection, genetic testing, drug discovery and patient-focused outcomes.

17 Jan 2012

Survey reveals high interest in Xalkori among medical oncologists

According to survey results gathered from 80 Medical Oncologists in the United States there is an extreme interest in Xalkori, with 75% of respondents stating a high interest in prescribing the product, virtually no physicians stating they have low interest in prescribing the therapy.

13 Jan 2012

Chemotherapy drugs can lead to relapse of leukemia

The chemotherapy drugs required to push a common form of adult leukemia into remission may contribute to DNA damage that can lead to a relapse of the disease in some patients, findings of a new study suggest.

12 Jan 2012

Occasional marijuana use does not affect lung function: Study

A new study published in the Journal of the American Medical Association has shown that an occasional drag on marijuana does not appear to have long-term adverse effects on lung function.

11 Jan 2012

Erlotinib better for treatment of non-small cell lung cancers

Researchers at Johns Hopkins have shown that DNA changes in a gene that drives the growth of a form of lung cancer can make the cancer's cells resistant to cancer drugs.

11 Jan 2012

Agilent, Integrated Diagnostics partner to improve protein-based LC/MS assays

Agilent Technologies Inc. and Integrated Diagnostics today announced a strategic partnership to develop assays that detect major human diseases at very early stages to improve treatment outcomes.

11 Jan 2012

Tobacco more harmful to lungs than marijuana

A large-scale national study suggests low to moderate use of marijuana is less harmful to users' lungs than exposure to tobacco, even though the two substances contain many of the same components. This comprehensive study, led by UCSF and University of Alabama at Birmingham, collected data from more than 5,000 U.S. adults for more than 20 years.

11 Jan 2012

Scientists identify key tumorigenic pathways in never-smoker lung adenocarcinoma patients

Researchers at the Translational Genomics Research Institute (TGen) have begun to identify mutations and cellular pathway changes that lead to lung cancer in never-smokers - a first step in developing potential therapeutic targets.

9 Jan 2012

Circadian initiates VGX-100 Phase 1 trial in advanced solid tumours

Circadian Technologies Limited announced today that it has commenced the first Phase 1 clinical trial of its fully human monoclonal antibody against VEGF-C, VGX-100, at a leading US-based cancer treatment centre.

9 Jan 2012

AccuGenomics to participate in OneMedForum at Sir Francis Drake hotel

AccuGenomics announced today that it will be attending the upcoming OneMedForum at the Sir Francis Drake hotel in San Francisco on January 9-12, coinciding with the JP Morgan Global Healthcare Conference.

7 Jan 2012

Study shows high consistency of malignancy-risk gene signature on both breast cancer and NSCLC

A malignancy-risk gene signature developed for breast cancer has been found to have predictive and prognostic value for patients with early stage non-small cell lung cancer. The advancement was made by researchers at Moffitt Cancer Center in Tampa, Fla., who published their study results in a recent issue of the Journal of the National Cancer Institute.

7 Jan 2012